Biosect - quote: "I’ve seen companies stay flat even on approval by the FDA and then go on to have hugely successful drugs and a massive market cap." I have considered the possibility of a lackluster response to an approval by the market. The impressive accomplishments of the company on both delivering stat sig end points, and herculean manufacturing prep, through certifications should have translated to higher SPs IMO. However, I've resigned myself to blaming the OTC and the lack of enforcement, especially on the OTC, that allows ongoing manipulation uncontested. IMO, the real unabated potential should commence upon the up-listing, which we know through hirings for that project has been underway for when that time arrives. To sum up, I've adjusted my expectations accordingly, and my willingness to do so to date has kept me calm in light of everything that has occurred until now.
ILT
Market Data 
Markets 
AI
